Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD

NCT05165394 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

93

Enrollment

INDUSTRY

Sponsor class

Conditions

Anhedonia
Major Depressive Disorder

Interventions

DRUG: Placebo
DRUG: NBI-1065846

Sponsor

Neurocrine Biosciences